Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial
Stanley TL, Feldpausch MN, Oh J, et al. JAMA 2014;312:380-389.
What it found
Visceral fat changed -34 cm² with tesamorelin vs +8 cm² with placebo, and liver fat fell (net effect -2.9% in lipid-to-water ratio). Fasting glucose rose more with tesamorelin at 2 weeks, but glucose differences at 6 months were not significant.
Limitations
Small single-centre study (48 received the study drug). Liver fat was measured by imaging, not biopsy.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.